Program
lenbelintide
Also written as “AZD6234”, “Lenbelintide” and “AZD6234 solution for injection”.
Its studies are mostly in Obesity · Lymphoma, Follicular · Diabetes Mellitus, Type 2 · Renal Insufficiency · Overweight, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 169 open or running | phase 3since Aug 5, 2026 | Aug 19, 2022 | Jan 29, 2027phase 2 · NCT06151964 |
- Named in AstraZeneca’s own pipeline as
lenbelintide (AZD6234)
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: quotient-sciences and parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 19, 2022First study: phase 1 study in OverweightFirst studyNCT05511025 · 54 enrolled · United States
- Sep 22, 2023Phase 2 study in OverweightNCT06151964 · 166 enrolled · Austria, Canada, Germany and more
- Nov 10, 2023Phase 1 study in OverweightNCT06132841 · 104 enrolled · United States, Japan
- Sep 11, 2024Phase 2 study in ObesityNCT06595238 · 262 enrolled · United States, Australia, Canada and more
- Feb 13, 20252 phase 2 studiesNCT06851858, NCT06862791
- Feb 24, 2025Phase 1 study in Renal InsufficiencyNCT06845813 · 24 enrolled · United States
- May 14, 2025Phase 2 study in ObesityNCT07017179 · 16 enrolled · China
- Jun 2, 2025Phase 1 study in ObesityNCT07013643 · 100 enrolled · United States
- Oct 23, 2025Phase 1 study in ObesityNCT07220954 · 19 enrolled · United Kingdom
- Mar 11, 2026Phase 1 study in Lymphoma, FollicularNCT07546760 · 28 planned · United States
- Aug 5, 20263 phase 3 studies in ObesityPhase 3 reachedNCT07784725, NCT07784270, NCT07776509
- Sep 29, 2026Primary completion moved from 2026-08-06 to 2026-10-23Date moved laterphase 2 · +3 months · NCT07017179
- Oct 13, 2026Phase 3 study in ObesityNCT07922330 · 330 planned · China, India
- Oct 26, 2026Phase 1 study in ObesityNCT07911514 · 60 planned · United Kingdom
Ahead
- Jan 29, 2027Primary completion: phase 2 study in OverweightNCT06151964
- Feb 4, 2027Primary completion: phase 1 study in Lymphoma, FollicularNCT07546760
- May 4, 2027Primary completion: phase 1 study in ObesityNCT07911514
- Jul 9, 2027Primary completion: phase 1 study in ObesityNCT07013643
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07911514Obesity · United Kingdom | 1 | Not yet recruiting | May 4, 2027 | 60 |
| NCT07922330Obesity · China, India | 3 | Not yet recruiting | Sep 15, 2028 | 330 |
| NCT07776509Obesity · United States, Argentina, Brazil and more | 3 | Recruiting | Aug 9, 2028 | 500 |
| NCT07784270Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Aug 9, 2028 | 1,500 |
| NCT07784725Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Aug 11, 2028 | 2,500 |
| NCT07546760Lymphoma, Follicular · United States | 1 | Recruiting | Feb 4, 2027 | 28 |
| NCT07220954Obesity · United Kingdom | 1 | Completed | Sep 16, 2026 | 19 |
| NCT07013643Obesity · United States | 1 | Active, not recruiting | Jul 9, 2027 | 100 |
| NCT07017179Obesity · China | 2 | Active, not recruiting | Oct 23, 2026 | 16 |
| NCT06845813Renal Insufficiency · United States | 1 | Completed | Sep 30, 2025 | 24 |
| NCT06862791Obesity · United States, Australia, Canada and more | 2 | Completed | May 11, 2026 | 377 |
| NCT06851858Diabetes Mellitus, Type 2 · United States | 2 | Completed | May 26, 2026 | 69 |
| NCT06595238Obesity · United States, Australia, Canada and more | 2 | Completed | Dec 3, 2025 | 262 |
| NCT06132841Overweight · United States, Japan | 1 | Completed | Feb 3, 2026 | 104 |
| NCT06151964Overweight · Austria, Canada, Germany and more | 2 | Active, not recruiting | Jan 29, 2027 | 166 |
| NCT05511025Overweight · United States | 1 | Completed | Dec 19, 2023 | 54 |
How it is read
Names in the registry
- “AZD6234”, 10 entries
- “Lenbelintide”, 3 entries
- “AZD6234 solution for injection”, 1 entry
- “AZD9550 and AZD6234”, 1 entry
- “AZD6234 Formulation 1”, 1 entry
Codes read as this program: AZD6234.
Conditions, from the studies’ own filings
- Obesity, 12 studies
- Lymphoma, Follicular, 1 study
- Diabetes Mellitus, Type 2, 1 study
- Renal Insufficiency, 1 study
- Overweight, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.